Peptonic Medical AB (“Peptonic” or the “Company”) has appointed Mangold Fondkommission as liquidity provider for the Company”s shares listed on Spotlight Stock Market.
A liquidity provider’s aim is to improve the liquidity of a share and reduce the spread between the bidding and asking price. Mangold Fondkommission’s assignment commences on September 27, 2023.
Mangold will fulfill its assignment as liquidity provider to ensure the possibility of trading in Peptonic’s share every day by continuously placing trading records on each purchase and sales page in the order book. A liquidity provider aims to create a more accurate pricing of a company”s share, which in turn gives a more accurate valuation of the company and allows for an improved trading volume in the share.
Erik Sundquist, CEO
Telefon: + 46 722 49 90 43
E-post: erik.sundquist@peptonicmedical.se
About PEPTONIC medical AB
Peptonic is a Swedish innovative biomedical company that conducts research, development and sales of medical treatments and lifestyle products in the field of women’s health. Peptonic has divided its operations into two business areas: “Medical Consumer” and “Lifestyle Consumer”. The “Medical Consumer” business area is based on clinically proven intimate self-care and is the company’s main focus and is sold under the VagiVital brand. The “Lifestyle Consumer” business area consists of lifestyle products with a focus on menstruation, sex and fertility and is sold under the Lunette brand. The company was founded in 2009 and the share has been traded on Spotlight (www.spotlightstockmarket.com) in Stockholm since 2014.
